A
Andy J. Ommen
Researcher at Durham University
Publications - 9
Citations - 369
Andy J. Ommen is an academic researcher from Durham University. The author has contributed to research in topics: Prodrug & Biological target. The author has an hindex of 7, co-authored 9 publications receiving 347 citations.
Papers
More filters
Journal ArticleDOI
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Kenneth He Huang,James Marvin Veal,Patrick Fadden,John W. Rice,Jeron Eaves,Jon-Paul Strachan,Amy F. Barabasz,Briana Foley,Barta Thomas E,Wei Ma,Melanie Silinski,Mei Hu,Jeffrey M. Partridge,Anisa Scott,Laura G. Dubois,Tiffany Freed,Paul M. Steed,Andy J. Ommen,Emilie D. Smith,Philip F. Hughes,Angela R. Woodward,Hanson Gunnar J,W. Stephen Mccall,Christopher John Markworth,Lindsay Hinkley,Matthew Jenks,Geng Lifeng,Meredith Lewis,James C. Otto,Bert Pronk,Katleen Verleysen,Steven E. Hall +31 more
TL;DR: A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library, and optimized analogues exhibited nanomolar antiproliferative activity across multiple cancer cell lines.
Journal ArticleDOI
Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90.
Patrick Fadden,Kenneth He Huang,James Marvin Veal,Paul M. Steed,Amy F. Barabasz,Briana Foley,Mei Hu,Jeffrey M. Partridge,John W. Rice,Anisa Scott,Laura G. Dubois,Tiffany Freed,Melanie Silinski,Barta Thomas E,Philip F. Hughes,Andy J. Ommen,Wei Ma,Emilie D. Smith,Angela Woodward Spangenberg,Jeron Eaves,Hanson Gunnar J,Lindsay Hinkley,Matthew Jenks,Meredith Lewis,James C. Otto,Gijsbertus J. Pronk,Katleen Verleysen,Timothy A.J. Haystead,Steven E. Hall +28 more
TL;DR: The chemoproteomics-based approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clinical studies.
Patent
2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives
TL;DR: In this paper, compounds of formula (I): (Formula (I) where X, Y, X, A, R1; R2, and R3 are defined).
Patent
Quinazoline derivatives for the treatment of cancer
TL;DR: The current invention is directed toward compounds and pharmaceutically acceptable salts of Formula I as discussed by the authors where Q 1 is CR 1, Q 2 is N, Q 4 and Q 5 are each CR 1, Q 3 is CR 2, X 1 is N or CRc, Y is CR c, X 2 and X 3 are each C(R 5 )(R 6 ), R 7 is O.
Patent
Tetrahydroindole and tetrahydroindazole derivatives
Kenneth He Huang,Andy J. Ommen,Thomas E. Barta,Philip Hughes,James Marvin Veal,Wei Ma,Emilie D. Smith,Angela R. Woodward,W. Stephen Mccall +8 more
TL;DR: In this paper, the authors provide indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and disorders ameliorated by the inhibition of Heat-Shock Protein 90.